<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02004769</url>
  </required_header>
  <id_info>
    <org_study_id>ML28670</org_study_id>
    <nct_id>NCT02004769</nct_id>
  </id_info>
  <brief_title>Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer</brief_title>
  <official_title>Phase II Study of Trastuzumab in Combination With Chemotherapy (Docetaxel Plus Capecitabine) For First Line Treatment of Her2-Positive Advanced Gastric or Gastro-Esophageal Junction Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>307 Hospital of PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Suzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with inoperable, locally advanced or recurrent and/or HER2-positive metastatic
      gastric or gastro-esophageal junction cancer, with no prior treatment for metastatic disease
      are to be recruited in the study. In the current study, the efficacy and safety of
      Trastuzumab in combination with Capecitabine/Docetaxel will be evaluated in Chinese patients
      with HER2 positive advanced or recurrent gastric cancer.60 patients could provide adequate
      precision rather than controlling type I&amp;II error. Assuming the target PFS is 6.7m, 60
      patients will give 90% CI of (5.5, 8.4). Considering the 5% drop out rate, 65 patients will
      be enrolled.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II, multi-center, open label, single arm, interventional study. Patients with
      HER2-positive metastatic gastric or gastro-esophageal junction adenocarcinoma who have not
      received prior treatment for metastatic disease will be treated with trastuzumab(8 mg/kg
      loading dose followed by 6 mg/kg every 3 weeks ),Capecitabine(2000mg/m2d, d1-14,every 3
      weeks) and Docetaxel (60mg/m2 every 3 weeks for 6 cycles).All patients will continue to
      receive trastuzumab and Capecitabine until either disease progression, occurrence of
      unacceptable toxicity or withdrawal from the study for another reason.Primary endpoints is
      PFS and secondary endpoints are ORR, OS and Safety.Recruitment period:24 months;PFS follow-up
      period: 80% PFS events;OS follow-up period: 18 months or 80% OS events, whichever occurs
      first.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS(Progression-free survival )</measure>
    <time_frame>up to 4 years</time_frame>
    <description>The PFS was calculated from the initiation of chemotherapy to the date of disease progression or death,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR (Overall tumor response)</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Overall tumor response: This is defined as the occurrence of either a confirmed complete (CR) or a partial (PR) best overall response as determined by the RECIST criteria from confirmed radiographic evaluations of target and non-target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS (Overall survival )</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Overall survival was measured from the initiation of chemotherapy to the date of the last follow-up or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Adverse events and laboratory tests graded according to the NCI-CTC AE Version 4.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Stomach Neoplasms</condition>
  <condition>Neoplasms Metastasis</condition>
  <condition>ERBB2 Gene Amplification</condition>
  <arm_group>
    <arm_group_label>Trastuzumab, Capecitabine, Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trastuzumab(8 mg/kg loading dose followed by 6 mg/kg every 3 weeks) Capecitabine(2000mg/m2d, d1-14,every 3 weeks) Docetaxel (60mg/m2 every 3 weeks for 6 cycles).All patients will continue to receive trastuzumab and Capecitabine until either disease progression, occurrence of unacceptable toxicity or withdrawal from the study for another reason.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab (Herceptin) will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks (q3w), until disease progress or intolerable toxicity.</description>
    <arm_group_label>Trastuzumab, Capecitabine, Docetaxel</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 60mg/m2 (on day 1) every 3 weeks for 6 cycles.</description>
    <arm_group_label>Trastuzumab, Capecitabine, Docetaxel</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine (Xeloda) 2000mg/m2d, d1-14, every 3 weeks until disease progress or intolerable toxicity.</description>
    <arm_group_label>Trastuzumab, Capecitabine, Docetaxel</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female. Age: 18-75 years.

          2. Histologically confirmed adenocarcinoma of the stomach or gastro-esophageal junction
             with inoperable locally advanced or recurrent and/or metastatic disease, not amenable
             to curative therapy.

          3. Measurable disease, according to the Response Evaluation Criteria in Solid Tumors
             (RECIST) version 1.1, assessed using imaging techniques (CT or MRI).

          4. HER2 positive tumor (primary tumor or metastasis, HER2 positive as defined by IHC2+
             and a confirmatory FISH+ result (HER2:CEP17 ratio ≥2), or by an IHC 3+ result) as
             assessed by the central laboratory. Accurate and validated assay methods will be used.

          5. ECOG Performance status 0-1.

          6. Life expectancy of at least 3 months.

          7. Signed informed consent.

          8. Previous chemotherapy for advanced/metastatic disease (prior adjuvant/neoadjuvant
             therapy is allowed if at least 6 months has elapsed between completion of
             adjuvant/neoadjuvant therapy and enrollment into the study; adjuvant/neoadjuvant
             therapy with docetaxel is not allowed).

        9 .Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome
        (e.g. patients with partial or total gastrectomy can enter the study, but not those with a
        jejunostomy probe).

        10. Patients with active (significant or uncontrolled) gastrointestinal bleeding.

        11. Residual relevant toxicity resulting from previous therapy (with the exception of
        alopecia), e.g. neurologic toxicity ≥ grade 2 NCI-CTCAE version 4.0.

        12. Other malignancy within the last 5 years, except for carcinoma in situ of the cervix,
        or basal cell carcinoma.

        13. Hematologic, Biochemical and Organ Function 14. Neutrophil count &lt; 1.5 × 109/L, or
        platelet count &lt; 100 × 109/L. 15. Serum bilirubin &gt; 1.5 × upper limit of normal (ULN); or,
        AST or ALT &gt; 2.5 × ULN (or &gt; 5 × ULN in patients with liver metastases); or, alkaline
        phosphatase &gt; 2.5 × ULN (or &gt; 5 × ULN in patients with liver metastases, or &gt; 10 × ULN in
        patients with bone but no liver metastases); or albumin &lt; 25 g/L.

        16. Creatinine clearance &lt; 60 mL/min.

        Exclusion Criteria:

          1. History of documented congestive heart failure; angina pectoris requiring medication;
             evidence of transmural myocardial infarction on ECG; poorly controlled hypertension
             (systolic BP &gt; 180 mmHg or diastolic BP &gt; 100 mmHg); clinically significant valvular
             heart disease; or high risk uncontrollable arrhythmias.

          2. Baseline LVEF &lt; 50% (measured by echocardiography or MUGA).

          3. Patients with dyspnea at rest due to complications of advanced malignancy or other
             disease, or who require supportive oxygen therapy.

          4. Patients receiving chronic or high dose corticosteroid therapy. (Inhaled steroids and
             short courses of oral steroids for anti-emesis or as an appetite stimulant are
             allowed).

          5. Known dihydropyrimidine dehydrogenase (DPD) deficiency.

          6. History or clinical evidence of brain metastases.

          7. Serious uncontrolled systemic intercurrent illness, e.g. infections or poorly
             controlled diabetes.

          8. Positive serum pregnancy test in women of childbearing potential.

          9. Subjects with reproductive potential not willing to use an effective method of
             contraception.

         10. Received any investigational drug treatment within 4 weeks of start of study
             treatment.

         11. Radiotherapy within 4 weeks of start of study treatment (2 week interval allowed if
             palliative radiotherapy given to bone metastatic site peripherally and patient
             recovered from any acute toxicity).

         12. Major surgery within 4 weeks of start of study treatment, without complete recovery.

         13. Patients with known active infection with HIV, HBV, or HCV.

         14. Known hypersensitivity to any of the study drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruihua Xu, M.D,Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Oncology,Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res. 1998 Apr;4(4):1013-9.</citation>
    <PMID>9563897</PMID>
  </reference>
  <reference>
    <citation>Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19. Erratum in: Lancet. 2010 Oct 16;376(9749):1302.</citation>
    <PMID>20728210</PMID>
  </reference>
  <reference>
    <citation>Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F; Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007 Aug 1;25(22):3217-23.</citation>
    <PMID>17664469</PMID>
  </reference>
  <reference>
    <citation>Thuss-Patience PC, Kretzschmar A, Repp M, Kingreen D, Hennesser D, Micheel S, Pink D, Scholz C, Dörken B, Reichardt P. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol. 2005 Jan 20;23(3):494-501.</citation>
    <PMID>15659494</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2013</study_first_submitted>
  <study_first_submitted_qc>December 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <last_update_submitted>November 17, 2016</last_update_submitted>
  <last_update_submitted_qc>November 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Ruihua Xu</investigator_full_name>
    <investigator_title>Vice-president and Professor</investigator_title>
  </responsible_party>
  <keyword>Metastatic gastric or gastro-esophageal junction cancer</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>HER2-positive</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>First-line therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

